Do analysts recommend RADX or AADI?

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Radiopharm Theranostics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, RADX or AADI?

Radiopharm Theranostics has higher earnings, but lower revenue than Aadi Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A Aadi Bioscience $25.07M 3.42 -$65.76M -$2.35 N/A

Which has higher valuation & earnings, CRDF or RADX?

Radiopharm Theranostics has higher revenue and earnings than Cardiff Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $590K 142.40 -$45.85M -$0.60 N/A Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A

Does the media refer more to CRDF or RADX?

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 2 mentions for Cardiff Oncology. Radiopharm Theranostics' average media sentiment score of 0.03 beat Cardiff Oncology's score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RADX or CTOR?

Radiopharm Theranostics currently has a consensus price target of $11.00, suggesting a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Radiopharm Theranostics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, RADX or CTOR?

Citius Oncology has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is RADX or CTOR more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Citius Oncology N/A -102.98% -43.49%

Which has higher valuation & earnings, RADX or RLYB?

Rallybio has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A Rallybio $646K 139.93 -$8.98M -$4.34 N/A

Which has better earnings and valuation, ACRV or RADX?

Radiopharm Theranostics has higher revenue and earnings than Acrivon Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A

Is ACRV or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% Radiopharm Theranostics N/A N/A N/A

Does the media favor ACRV or RADX?

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.03 beat Acrivon Therapeutics' score of -0.14 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Radiopharm Theranostics (RADX) Competitors

$1.13 +0.02 (+1.80%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.12 -0.01 (-0.80%)

As of 10/9/2026 07:00 PM Eastern

Compare

RADX vs. AADI, CRDF, CTOR, RLYB, and ACRV

Should you buy Radiopharm Theranostics stock or one of its competitors? Radiopharm Theranostics's main competitors and comparable companies include Aadi Bioscience (AADI), Cardiff Oncology (CRDF), Citius Oncology (CTOR), Rallybio (RLYB), and Acrivon Therapeutics (ACRV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Radiopharm Theranostics compare to Aadi Bioscience?

Radiopharm Theranostics (NASDAQ:RADX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Radiopharm Theranostics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Radiopharm Theranostics' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

52.1% of Aadi Bioscience shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Radiopharm Theranostics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Radiopharm Theranostics has higher earnings, but lower revenue than Aadi Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A
Aadi Bioscience	$25.07M	3.42	-$65.76M	-$2.35	N/A

In the previous week, Radiopharm Theranostics had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 0 mentions for Aadi Bioscience. Radiopharm Theranostics' average media sentiment score of 0.03 beat Aadi Bioscience's score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Aadi Bioscience	Neutral

Summary

Radiopharm Theranostics beats Aadi Bioscience on 11 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Radiopharm Theranostics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Radiopharm Theranostics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Radiopharm Theranostics	N/A	N/A	N/A

Cardiff Oncology presently has a consensus price target of $7.50, indicating a potential upside of 594.44%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, analysts clearly believe Radiopharm Theranostics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Radiopharm Theranostics has higher revenue and earnings than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	142.40	-$45.85M	-$0.60	N/A
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A

16.3% of Cardiff Oncology shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cardiff Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 2 mentions for Cardiff Oncology. Radiopharm Theranostics' average media sentiment score of 0.03 beat Cardiff Oncology's score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Radiopharm Theranostics beats Cardiff Oncology on 10 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Citius Oncology?

Radiopharm Theranostics (NASDAQ:RADX) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Radiopharm Theranostics currently has a consensus price target of $11.00, suggesting a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Radiopharm Theranostics' return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Citius Oncology	N/A	-102.98%	-43.49%

Radiopharm Theranostics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.39, indicating that its stock price is 239% more volatile than the broader market.

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 2 mentions for Citius Oncology. Radiopharm Theranostics' average media sentiment score of 0.03 beat Citius Oncology's score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Citius Oncology	Neutral

70.5% of Citius Oncology shares are held by institutional investors. 9.8% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Citius Oncology has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Summary

Radiopharm Theranostics beats Citius Oncology on 8 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Rallybio?

Radiopharm Theranostics (NASDAQ:RADX) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

In the previous week, Radiopharm Theranostics had 2 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 1 mentions for Rallybio. Radiopharm Theranostics' average media sentiment score of 0.03 beat Rallybio's score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Rallybio	Neutral

Radiopharm Theranostics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Radiopharm Theranostics' return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Rallybio	-911.07%	-40.53%	-38.13%

Radiopharm Theranostics currently has a consensus target price of $11.00, indicating a potential upside of 873.45%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, research analysts plainly believe Radiopharm Theranostics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rallybio has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A
Rallybio	$646K	139.93	-$8.98M	-$4.34	N/A

Radiopharm Theranostics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.72, suggesting that its share price is 172% less volatile than the broader market.

90.3% of Rallybio shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Radiopharm Theranostics beats Rallybio on 10 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 3 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.03 beat Acrivon Therapeutics' score of -0.14 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Radiopharm Theranostics has higher revenue and earnings than Acrivon Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Radiopharm Theranostics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Radiopharm Theranostics	N/A	N/A	N/A

Acrivon Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

Acrivon Therapeutics presently has a consensus target price of $13.50, indicating a potential upside of 606.81%. Radiopharm Theranostics has a consensus target price of $11.00, indicating a potential upside of 873.45%. Given Radiopharm Theranostics' higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Acrivon Therapeutics and Radiopharm Theranostics tied by winning 6 of the 12 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.43M	$3.86B	$7.17B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	N/A	13.42	274.15	26.16
Price / Sales	9.44	1,234.39	635.99	107.44
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.88	17.17	11.22	6.33
Net Income	-$38.65M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-20.42%	-1.34%	-0.90%	-1.40%
1 Month Performance	-45.15%	-8.45%	-4.44%	-3.47%
1 Year Performance	-83.93%	14.03%	7.02%	1.19%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	3.4485 of 5 stars	$1.13 +1.8%	$11.00 +873.5%	-84.8%	$17.43M	$1.88M	N/A	14
AADI Aadi Bioscience	N/A	$3.76 flat	N/A	+62.9%	$92.86M	$25.07M	N/A	40	Gap Up
CRDF Cardiff Oncology	1.7348 of 5 stars	$1.12 -5.1%	$7.50 +569.6%	-54.6%	$91.80M	$590K	N/A	31	Analyst Upgrade Gap Up
CTOR Citius Oncology	0.7692 of 5 stars	$0.95 -3.1%	N/A	-54.1%	$91.12M	N/A	N/A	N/A	Short Interest Decrease
RLYB Rallybio	1.2869 of 5 stars	$17.08 +1.9%	N/A	+284.4%	$89M	$860K	N/A	40	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. AADI, CRDF, CTOR, RLYB, and ACRV

How does Radiopharm Theranostics compare to Aadi Bioscience?

Summary

How does Radiopharm Theranostics compare to Cardiff Oncology?

Summary

How does Radiopharm Theranostics compare to Citius Oncology?

Summary

How does Radiopharm Theranostics compare to Rallybio?

Summary

How does Radiopharm Theranostics compare to Acrivon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. AADI, CRDF, CTOR, RLYB, and ACRV

How does Radiopharm Theranostics compare to Aadi Bioscience?

Is RADX or AADI more profitable?

Do analysts recommend RADX or AADI?

Do insiders and institutionals have more ownership in RADX or AADI?

Which has more risk & volatility, RADX or AADI?

Which has preferable earnings and valuation, RADX or AADI?

Does the media favor RADX or AADI?

Summary

How does Radiopharm Theranostics compare to Cardiff Oncology?

Is CRDF or RADX more profitable?

Do analysts rate CRDF or RADX?

Which has higher valuation & earnings, CRDF or RADX?

Do institutionals & insiders believe in CRDF or RADX?

Which has more risk & volatility, CRDF or RADX?

Does the media refer more to CRDF or RADX?

Summary

How does Radiopharm Theranostics compare to Citius Oncology?

Do analysts recommend RADX or CTOR?

Is RADX or CTOR more profitable?

Which has more risk and volatility, RADX or CTOR?

Does the media favor RADX or CTOR?

Do institutionals & insiders hold more shares of RADX or CTOR?

Which has higher earnings & valuation, RADX or CTOR?

Summary

How does Radiopharm Theranostics compare to Rallybio?

Does the media favor RADX or RLYB?

Is RADX or RLYB more profitable?

Do analysts rate RADX or RLYB?

Which has higher valuation & earnings, RADX or RLYB?

Which has more risk and volatility, RADX or RLYB?

Do insiders and institutionals have more ownership in RADX or RLYB?

Summary

How does Radiopharm Theranostics compare to Acrivon Therapeutics?

Does the media favor ACRV or RADX?

Which has better earnings and valuation, ACRV or RADX?

Do institutionals & insiders believe in ACRV or RADX?

Is ACRV or RADX more profitable?

Which has more volatility & risk, ACRV or RADX?

Do analysts prefer ACRV or RADX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools